Sun 7 Sep 2008 | 0:56 EDT
You are here: Home > News > Article
Home
Business & Finance
News
U.S.
Politics
International
Technology
Entertainment
Sports
Lifestyle
Oddly Enough
Environment
Health
Science
Special Coverage
Video
Pictures
You Witness
Blogs
Reader Feedback
Do More With Reuters
RSSRSS Feed
Widgets
Mobile
Podcasts
Newsletters
You Witness News
Partner Services
CareerBuilder
Affiliate Network
Professional Products
Support (Customer Zone)
Reuters Media
Financial Products
About Thomson Reuters

OXiGENE begins pivotal registration study for Zybrestat in anaplastic thyroid cancer

Mon Jul 9, 2007 2:00pm EDT
 
Email | Print | | Reprints | Single Page
[-] Text [+]
Co announces it has begun a pivotal registration study of its first-in-class vascular disrupting agent, Zybrestat (combretastatin-A4 phosphate / CA4P), in patients with metastatic anaplastic thyroid cancer.

 

Also on reuters

Featured Broker sponsored link

Editor's Choice

  • Pictures
  • Video
  • Articles
Photo

A selection of our best photos from the past 24 hours.  View Slideshow 

Most Popular on Reuters

  • Articles
  • Video
  • Recommended

Are you going to the conventions?

Reuters is looking for participants in a new mobile journalism project to capture the Republican and Democratic conventions from the ground up.

Learn More